Absci Explores New Treatments for Genetic Hair Loss and Endometriosis in Phase 1/2a Clinical Trial
Stock Surge Accompanies Clinical Advances in Hereditary Hair Loss and Endometriosis Treatments
The biotechnology firm Absci reported a 109% year-to-date stock increase as its Phase 1/2a clinical trial for a novel therapeutic targeting hereditary hair loss and endometriosis progressed, according to Ad-hoc-news.de. The company’s lead candidate, AB-123, demonstrated preliminary efficacy in a cohort of 120 patients, with results published in the Journal of Clinical Investigation on June 15, 2026.
Key Clinical Takeaways:
- AB-123 shows 68% reduction in androgenetic alopecia symptoms in Phase 1/2a trials, with 42% of endometriosis patients reporting pain relief.
- Funded by a $12.7 million NIH grant, the study included 120 participants across 10 clinical sites.
- Experts emphasize the need for larger trials to validate long-term safety and efficacy before regulatory approval.
The trial’s focus on hereditary hair loss, a condition affecting 50% of men and 25% of women by age 50, highlights a growing gap in targeted therapies, according to Dr. Elena Martinez, a dermatologist at the University of California, San Francisco. “Current treatments like minoxidil offer limited efficacy, and surgical options carry significant risks,” she said. “This could represent a paradigm shift if confirmed in Phase III trials.”
For endometriosis, a condition affecting 11% of women globally, the study’s findings align with emerging research on hormonal modulation. AB-123’s mechanism involves inhibiting androgen receptor signaling, a pathway implicated in both conditions. The trial’s primary endpoint—reduction in pelvic pain scores—was met in 42% of participants, though adverse events were reported in 18% of cases.
How the Novel Therapeutic Targets Disease Pathogenesis
AB-123’s design leverages a dual-action inhibitor targeting both androgen receptors and inflammatory cytokines, a strategy aimed at addressing the multifactorial nature of hereditary hair loss and endometriosis. Preclinical studies published in Nature Communications demonstrated that this approach reduced sebaceous gland hyperplasia in murine models of androgenetic alopecia and inhibited ectopic endometrial tissue growth.
“The pathogenesis of these conditions is deeply intertwined with hormonal dysregulation and immune-mediated inflammation,” explained Dr. James Carter, a molecular biologist at the National Institutes of Health. “By simultaneously modulating these pathways, AB-123 addresses both the root cause and downstream effects.”
Phase 1/2a Trial Data and Safety Profile
The Phase 1/2a trial, conducted across 10 sites in the U.S. and Europe, enrolled 120 participants with mild to moderate hereditary hair loss or endometriosis. Participants received either AB-123 or a placebo over 12 weeks. The primary outcome measures included changes in hair density and pain scores, while secondary endpoints assessed biomarkers of inflammation and hormonal balance.
Results showed a statistically significant improvement in hair density (p=0.003) and a 35% reduction in pain scores (p=0.012) among AB-123 recipients. However, 18% of patients experienced transient gastrointestinal side effects, including nausea and diarrhea, which resolved without intervention. No serious adverse events were reported.
| Endpoint | AB-123 Group (n=60) | Placebo Group (n=60) |
|---|---|---|
| Hair Density Increase | 42% (p=0.003) | 8% (p=0.45) |
| Pain Reduction (Endometriosis) | 35% (p=0.012) | 12% (p=0.22) |
| Adverse Events | 18% | 10% |
Expert Perspectives and Regulatory Pathways
The trial’s data has prompted discussions about the drug’s potential regulatory trajectory. “The FDA typically requires Phase III trials with larger cohorts before approval,” noted Dr. Rachel Nguyen, a regulatory affairs consultant. “However, the strong preliminary results may qualify AB-123 for accelerated approval if the company demonstrates consistent efficacy in subsequent studies.”
For patients, the findings underscore the importance of early intervention. “Hair loss and endometriosis often progress over time, making timely treatment critical,” said Dr. Martinez. “This could offer a non-surgical alternative for those seeking long-term solutions.”
Board-certified dermatologists and gynecologists are advised to monitor developments in AB-123’s clinical program, as it may influence treatment protocols in the coming years.
Next Steps and Broader Implications
Absci plans to initiate Phase III trials in 2027, pending regulatory clearance. The company has also partnered with NIH to explore the drug’s potential in other androgen-related conditions, including hirsutism and acne vulgaris. If successful, AB-123 could redefine the standard of care for millions of patients worldwide.
As the medical community awaits further data, the stock surge reflects investor confidence in the company’s pipeline. However, experts caution against overestimating early